Tyra Biosciences, Inc. Stock Price, News & Analysis

Tyra Biosciences (Nasdaq: TYRA) will present preclinical data on its FGFR1/2/3 inhibitor, TYRA-200, at the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain, from October 26-28, 2022. The presentation is scheduled for October 26 and focuses on TYRA-200's effectiveness against FGFR2 fusions, molecular brake mutations, and gatekeeper resistance, with the aim of enhancing outcomes for cancer patients. This event is pivotal as the company seeks to advance its pipeline targeting critical genetic alterations affecting cancer treatment.

Tyra Biosciences (Nasdaq: TYRA), a precision oncology firm, announced its participation in key investor conferences. Management will present a pre-recorded session at H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022, with the presentation available on September 12 at 7 AM ET. Additionally, Tyra will be featured at the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022, with a panel discussion at 11:30 AM ET. Tyra is focused on therapies to overcome tumor resistance and is developing selective FGFR inhibitors.

Tyra Biosciences, Inc. (Nasdaq: TYRA) announced the presentation of preclinical data on TYRA-300, an FGFR3-selective inhibitor, at the ESMO 2022 Congress in Paris from September 9-13, 2022. CEO Todd Harris highlighted the promising anti-tumor activity of TYRA-300 compared to other agents. This data supports the upcoming SURF301 Phase 1/2 clinical study, which the FDA has already authorized. The poster presentation will occur on September 12, 2022, showcasing the drug's potential in treating metastatic urothelial carcinoma.

Tyra Biosciences announced the FDA's IND clearance for its SURF301 study of TYRA-300, an FGFR3-selective inhibitor for bladder cancer. The company is on track to file an IND for TYRA-200 in the second half of 2022 and reported a strong cash position of $275.1 million as of June 30, 2022. Despite progress, the net loss for Q2 2022 was $15.1 million, up from $5.5 million in Q2 2021, with increased R&D expenses of $12.0 million compared to $4.4 million from the prior year.

Tyra Biosciences (TYRA) reported its Q1 2022 financial results, highlighting a net loss of $14.8 million, up from $4.2 million in Q1 2021. Operating expenses rose significantly with research and development costs reaching $9.6 million and general administrative expenses at $5.2 million. The company has cash and equivalents of $292.5 million as of March 31, 2022, reassuring investors of its financial stability. Tyra plans to file INDs for its lead product candidates, TYRA-300 and TYRA-200, by mid-2022 and the second half of 2022, respectively.

Tyra Biosciences (Nasdaq: TYRA) reported its fourth quarter and full year 2021 financial results, highlighting a net loss of $9.9 million for Q4 and $26.3 million for the year, compared to $3.7 million and $9.3 million, respectively, in 2020. R&D expenses surged to $7.2 million in Q4 from $2.9 million a year prior, while total cash reached $302.2 million. Anticipated FDA IND submissions for TYRA-300 and TYRA-200 are planned for 2022, alongside a strengthening of the clinical team.

Tyra Biosciences (Nasdaq: TYRA) announced its participation in the Cowen 42nd Annual Healthcare Conference from March 7-9, 2022. CEO Todd Harris will be featured in a panel on March 8, 2022, at 9:10 am ET. The event aims to highlight the company's focus on precision oncology and its proprietary SNÅP platform to develop therapies targeting tumor resistance. Investors can access a live webcast on the company's website. Tyra specializes in inhibitors for the Fibroblast Growth Factor Receptor (FGFR) family, crucial in treating various cancers.

Tyra Biosciences (Nasdaq: TYRA) will participate in the 2021 Jefferies London Healthcare Conference on November 18-19, 2021. Management will host a fireside chat and one-on-one investor meetings, with the chat available on-demand from November 18. The company focuses on developing precision oncology therapies to combat tumor resistance, featuring their proprietary SNÅP platform. Their lead product, TYRA-300, targets bladder cancer, while TYRA-200 aims at intrahepatic cholangiocarcinoma.

Tyra Biosciences, Inc. (Nasdaq: TYRA) announced its financial results for the quarter ending September 30, 2021. The company completed a $198.7 million IPO and strengthened its leadership team with key appointments. Cash and cash equivalents reached $312.8 million, expected to fund operations through at least 2024. R&D expenses rose to $5.5 million, while net loss for the quarter was $6.6 million, or $(0.72) per share. TYRA nominated TYRA-200 for clinical development, targeting FGFR2 mutations.